Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - A scholarly case

Virology Journal

Volumn 7, Issue , 2010, Pages

  Schildgen, Verena ^a,d   Ziegler, Susanne ^b,c   Tillmann, Ramona L ^d   Schildgen, Oliver ^b,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; HEPON; LAMIVUDINE; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG; ADEFOVIR; ADENINE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ARTICLE; BONE PAIN; CASE REPORT; CHILD; DISORIENTATION; DRUG SUBSTITUTION; FEVER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; INCIDENCE; INSOMNIA; LIVER CELL CARCINOMA; MALE; PRESCHOOL CHILD; PROTEIN MOTIF; SCHOOL CHILD; STOP CODON; VIREMIA; VIRUS MUTATION; VIRUS STRAIN; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; CHEMISTRY; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MISSENSE MUTATION; MOLECULAR GENETICS; SEQUENCE ALIGNMENT; VIROLOGY;

HEPATITIS B VIRUS;

ADENINE; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CHILD; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHOSPHONIC ACIDS; SEQUENCE ALIGNMENT;

EID: 77954674316     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-167     Document Type: Article

References (14)

1. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. AS Lok F Zoulim S Locarnini, et al. J Clin Microbiol 2002 40 3729 34 10.1128/JCM.40.10.3729-3734.2002 12354872
2. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. D Lavanchy, J Viral Hepat 2004 11 97 107 10.1046/j.1365-2893.2003.00487.x 14996343
3. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. AS Lok F Zoulim S Locarnini, et al. Hepatology 2007 46 254 65 10.1002/hep.21698 17596850
4. Management of hepatitis B: summary of a clinical research workshop. JH Hoofnagle E Doo TJ Liang R Fleischer AS Lok, Hepatology 2007 45 1056 75 10.1002/hep.21627 17393513
5. An immunomodulator Hepon inhibits hepatitis C virus replication in human cell cultures in vitro. RIHRD Ataullakhanov AV Katlinski PG Deriabin AN Narovlianski MV Mezentseva FI Ershov, Antibiot Khimioter 2002 47 9 11 12515090
6. Variant of hepatitis B virus with primary resistance to adefovir. O Schildgen H Sirma A Funk, et al. N Engl J Med 2006 354 1807 12 10.1056/NEJMoa051214 16641397
7. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. O Schildgen CK Schewe M Vogel, et al. Aids 2004 18 2325 7 10.1097/00002030-200411190-00014 15577546
8. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. MM Bartholomew RW Jansen LJ Jeffers, et al. Lancet 1997 349 20 2 10.1016/S0140-6736(96)02266-0 8988118
9. Lamivudine as initial treatment for chronic hepatitis B in the United States. JL Dienstag ER Schiff TL Wright, et al. N Engl J Med 1999 341 1256 63 10.1056/NEJM199910213411702 10528035
10. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. JL Dienstag ER Schiff M Mitchell, et al. Hepatology 1999 30 1082 7 10.1002/hep.510300427 10498663
11. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. MI Allen M Deslauriers CW Andrews, et al. Hepatology 1998 27 1670 7 10.1002/hep.510270628 9620341
12. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. E Doo TJ Liang, Gastroenterology 2001 120 1000 8 10.1053/gast.2001.22454 11231955
13. Prevalence, incidence, and clinical relevance of the reverse transcriptase V207I mutation outside the YMDD motif of the hepatitis B virus polymerase during lamivudine therapy. B Zollner M Sterneck K Wursthorn, et al. J Clin Microbiol 2005 43 2503 5 10.1128/JCM.43.5.2503-2505.2005 15872296
14. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. P Angus R Vaughan S Xiong, et al. Gastroenterology 2003 125 292 7 10.1016/S0016-5085(03)00939-9 12891527